Thomas Richard Kassberg Ultragenyx Pharmaceutical Inc. (RARE) insider trading activity

Thomas Richard Kassberg is CBO & EVP of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 264,730 shares of RARE, which is worth approximately $10.5 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 6,028 shares (Common Stock) at a price of $42.1 per share, resulting in proceeds of $253,778. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 265K

4.71% 3M change

4.71% 12M change

Total Value Held $10.5 Million

Thomas Richard Kassberg Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Open market or private sale	$253,778 $42.1 p/Share	6,028 Reduced 2.22%	265,238 Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$21,803 $42.92 p/Share	508 Reduced 0.19%	264,730 Common Stock
Mar 01 2025	BUY Grant, award, or other acquisition	-	18,443 Added 6.37%	271,266 Common Stock
Mar 11 2024	SELL Open market or private sale	$574,644 $49.93 p/Share	11,509 Reduced 4.35%	252,823 Common Stock
Mar 01 2024	SELL Open market or private sale	$54,351 $53.76 p/Share	1,011 Reduced 0.38%	264,332 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$14,711 $53.69 p/Share	274 Reduced 0.1%	265,343 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	18,757 Added 6.6%	265,617 Common Stock
Oct 23 2023	SELL Open market or private sale	$1,307,200 $32.78 p/Share	39,878 Reduced 13.91%	246,860 Common Stock
Oct 23 2023	BUY Exercise of conversion of derivative security	$273,563 $6.86 p/Share	39,878 Added 12.21%	286,738 Common Stock
Mar 01 2023	SELL Open market or private sale	$89,091 $45.27 p/Share	1,968 Reduced 0.78%	250,254 Common Stock
Mar 01 2023	SELL Sale (or disposition) back to the issuer	$154,936 $45.65 p/Share	3,394 Reduced 1.36%	246,860 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	24,663 Added 8.91%	252,222 Common Stock
Mar 11 2022	SELL Open market or private sale	$688,930 $67.01 p/Share	10,281 Reduced 4.32%	227,559 Common Stock
Mar 01 2022	SELL Open market or private sale	$158,156 $66.62 p/Share	2,374 Reduced 1.1%	213,840 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	14,000 Added 5.79%	227,840 Common Stock
Oct 14 2021	SELL Open market or private sale	$23,206 $81.14 p/Share	286 Reduced 0.13%	216,266 Common Stock
Sep 30 2021	BUY Exercise of conversion of derivative security	$34,018 $0.31 p/Share	109,734 Added 33.63%	216,552 Common Stock
May 06 2021	SELL Open market or private sale	$41,269 $113.69 p/Share	363 Reduced 0.34%	106,818 Common Stock
Mar 01 2021	SELL Open market or private sale	$631,713 $138.17 p/Share	4,572 Reduced 4.09%	107,181 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	10,136 Added 8.33%	111,614 Common Stock
Oct 14 2020	SELL Open market or private sale	$23,051 $87.98 p/Share	262 Reduced 0.26%	101,478 Common Stock

Also insider at

PASG

Passage BIO, Inc. Healthcare

TRK